{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(1)"],"submitter":["Caliskan E"],"funding":["Somahlution"],"pubmed_abstract":["<h4>Background</h4>Vein graft disease (VGD) impairs graft patency rates and long-term outcomes after coronary artery bypass grafting (CABG). DuraGraft is a novel endothelial-damage inhibitor developed to efficiently protect the structural and functional integrity of the vascular endothelium. The DuraGraft registry will evaluate the long-term clinical outcomes of DuraGraft in patients undergoing CABG procedures.<h4>Methods</h4>This ongoing multicentre, prospective observational registry will enrol 3000 patients undergoing an isolated CABG procedure or a combined procedure (ie, CABG plus valve surgery or other surgery) with at least one saphenous vein grafts or one free arterial graft (ie, radial artery or mammary artery). If a patient is enrolled, all free grafts (SVG and arterial will be t"],"journal":["Journal of cardiothoracic surgery"],"pagination":["174"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6794868"],"repository":["biostudies-literature"],"pubmed_title":["A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry."],"pmcid":["PMC6794868"],"pubmed_authors":["Salzberg SP","Boning A","Emmert MY","Choi YH","Misfeld M","Satishchandran V","Caliskan E","Perrault LP","Sandner S","Aramendi J","Iyer G"],"additional_accession":[]},"is_claimable":false,"name":"A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry.","description":"<h4>Background</h4>Vein graft disease (VGD) impairs graft patency rates and long-term outcomes after coronary artery bypass grafting (CABG). DuraGraft is a novel endothelial-damage inhibitor developed to efficiently protect the structural and functional integrity of the vascular endothelium. The DuraGraft registry will evaluate the long-term clinical outcomes of DuraGraft in patients undergoing CABG procedures.<h4>Methods</h4>This ongoing multicentre, prospective observational registry will enrol 3000 patients undergoing an isolated CABG procedure or a combined procedure (ie, CABG plus valve surgery or other surgery) with at least one saphenous vein grafts or one free arterial graft (ie, radial artery or mammary artery). If a patient is enrolled, all free grafts (SVG and arterial will be t","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Oct","modification":"2026-05-03T21:58:53.372Z","creation":"2019-11-05T08:06:26Z"},"accession":"S-EPMC6794868","cross_references":{"pubmed":["31615560"],"doi":["10.1186/s13019-019-1010-z"]}}